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policies (single agent or combined chemotherapy, radio-
therapy, combined modality treatment) adopted and 
changed during the time period of 16 years of this retro-
spective study were documented. 
 Copyright © 2004 S. Karger AG, Basel 
 Introduction 
 The incidence of non-Hodgkin lymphoma (NHL), es-
pecially at certain extranodal sites continues to rise  [1] 
and the number of deaths attributable to these malignan-
cies rank in the top fi ve causes of cancer-related deaths in 
the United States  [2] . Their increasing incidence is re-
lated to the environmental factors including occupation-
al exposures and HIV infection  [3] . NHL arises either in 
lymph nodes or in other lymphatic tissues, such as spleen 
and mediastinum (‘nodal lymphomas’), or in lymphatic 
cells in other organs, such as tonsils and thymus (‘extra-
nodal lymphomas’)  [4] . 
 The Age Standardized Incidence Rate (ASIR) of NHL 
as reported by the Kuwait Cancer Registry (2002) is 
5.8/100,000 in Kuwaiti males and 8.5/100,000 in Ku-
waiti females. ASIR among non-Kuwaiti males is 
4.6/100,000 and 3.5/100,000 among non-Kuwaiti fe-
males. NHL ranks as the third most common cancer in 
both Kuwaiti males (after leukemia and lung cancer) and 
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 Abstract 
 A total of 935 patients with extranodal non-Hodgkin lym-
phoma (NHL) diagnosed in the period between January 
1985 and December 2000 in Kuwait Cancer Center, serv-
ing the whole population of Kuwait, were used to de-
scribe the clinicopathological and epidemiological fea-
tures of extranodal lymphomas in Kuwait. Extranodal 
lymphomas accounted for 45% of all NHL observed dur-
ing this time. All NHL cases from Kuwait Cancer registry 
were analyzed and pathologically reclassifi ed using the 
latest WHO (2000) classifi cation. The most common lym-
phoma observed was diffuse large B-cell lymphoma 
(58.60%) followed by Burkitt´s lymphoma (BL) (3.80%). 
In the pediatric group, BL comprises more than two 
thirds of all patients (77.20%). The most common extra-
nodal sites were stomach (19.70%) and skin (17.80%) in 
the adult group, large intestine (29.80%) and small intes-
tine (19.30%) in the pediatric age group. The majority 
(73.40%) of adult extranodal lymphomas was in stage 
IE–IIE and had a very good prognosis. On the contrary, 
the majority of pediatric extranodal lymphomas were 
found to be in stage III and IV. Variations in treatment 
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Kuwaiti and non-Kuwaiti females (after breast and thy-
roid cancer). NHL ranks two in male non-Kuwaiti pa-
tients after lung cancer. 
 The incidence of NHL arising from an extranodal tis-
sue has been reported to be increasing in several countries 
 [1, 5] and yet the epidemiology of this heterogeneous dis-
ease has been poorly described. Over the past three de-
cades, immunology, cytomorphological and genetic diag-
nostic techniques have continuously refi ned our current 
understanding of neoplasia of the immune system  [6] . 
Differences in presentation, behavior and survival be-
tween NHL of nodal and extranodal sites have led sev-
eral authors to suggest that nodal and extranodal diseases 
should be considered as distinct entities with differing 
etiologies  [7–9] . Although 25–45% of patients of NHL 
present with a primary extranodal lymphoma  [4, 7–10] , 
and numerous papers dealing with extranodal NHL orig-
inating in almost every organ in the body have been pub-
lished, the literature on primary extranodal lymphomas 
as a group is limited  [10] . In Kuwait, the incidence of ex-
tranodal lymphomas is 45% of all lymphomas registered 
during the last 16 years. In this retrospective study, the 
comprehensive data collected at the Hussain Makki Al 
Jummaa Cancer Center, the only institution serving the 
whole population of Kuwait, and the registries of all main 
general hospitals of Kuwait were evaluated to describe 
the epidemiology and pathoclinical features of extranod-
al lymphomas in Kuwait in the period from 1985 to 
2000. 
 Material and Methods 
 Clinicopathological data and site-specifi c information on NHL 
were obtained from registries of the Hussain Makki Al Jummaa 
Cancer Center in Kuwait, general hospitals in Kuwait and from 
patients outside of Kuwait referred to Kuwait Cancer Control Cen-
ter (KCCC) for the treatment of their disease. A total of 935 patients 
with extranodal NHL diagnosed in the period between January 
1985 and December 2000 in KCCC were studied. The information 
included age of the patients, sex, ethnic origin, date and site of the 
diagnostic biopsies, primary extranodal site of involvement, in-
cluding lymphatic sites when positive, performance status, diam-
eter of the largest tumor mass and Ann Arbor stage. 
 Laboratory data recorded included: serum lactate dehydroge-
nase level, absolute lymphocyte count, presence of circulating lym-
phoma cells, history of immunodefi ciency (HTLV-1), human im-
munodefi ciency virus status, hepatitis screening, bone marrow 
aspiration and biopsy. 
 Radiological investigations comprised of CT scan for chest, pel-
vis and abdomen. The neck was included when indicated. In se-
lected cases additional studies were performed: gallium scan, ST 
scan or MRI of brain, upper and lower GIT endoscopies, in cases 
with symptoms of GIT lymphomas or when tonsils of Waldeyer’s 
ring were involved. For special indications diagnostic lumbar punc-
tures (CSF examination, cytology and chemistry) were per-
formed. 
 Staging 
 The clinical stage at the time of initial diagnosis of the lympho-
mas was defi ned according to the Ann Arbor classifi cation. Involve-
ment of lymph nodes and mediastinum were defi ned as nodal lo-
calizations, and the involvement of other organs was defi ned as 
extranodal. Patient’s were considered to be completely staged when 
adequate information was available on history, status of periph-
eral lymph nodes (physical examination), Waldeyer’s ring examina-
tion, mediastinal lymph nodes (chest X-ray), abdominal lymph 
nodes, liver and spleen (abdominal CT scan) as well as on periph-
eral blood and bone marrow (cytology and histology). 
 Histopathological Evaluation 
 Routine hematoxylin-eosin stained sections were evaluated in 
all cases to assess general pathomorphological features. In addition 
to hematoxylin-eosin staining, immunophenotyping of all lympho-
mas was routinely done in our laboratory. lmmunohistochemical 
studies were performed on paraffi n-embedded tissue (extranodal 
sites and/or involved lymph nodes) from all patients using a three-
stage immuno-peroxidase technique after antigen retrieval by mi-
crowaving the slides in citrate buffer for 35 min. Primary antibod-
ies (obtained from Zymed Laboratories, San Francisco, Calif., 
USA) were used in this study: 
 The basic NHL screen panel to determine B- or T-cell pheno-
type in our practice included CD20 and CD3; A more accurate 
classifi cation of NHL was achieved by using other different mark-
ers: 
 In cases of small cell NHL, the panel included CD5, CD21, 
CD23 bcl-2, PRAD1, and   and   light chains. 
 Antibodies to CD15, CD30, CD45, EMA, and anaplastic lym-
phoma kinase were used to differentiate between peripheral T-cell 
lymphoma, anaplastic lymphoma and Hodgkin’s lymphoma. 
 In case of NHL with plasmocytic or plasmocytoid differentia-
tion, antibodies to  and   light chains were used to confi rm the 
diagnosis of these subtypes. 
 tDt, CD5, CD43, PRAD1, peroxidase or lysozyme were used 
to differentiate between lymphoblastic lymphoma, mantle cell lym-
phoma, and granulocytic sarcoma. 
 Additional immunostaining that was helpful for differential di-
agnosis included cytokeratin, LCA (CD45), Ki-67 (M1B1), bcl-2, 
CD34, c-myc, CD10 and bcl-6. 
 Positive controls were prepared using paraffi n-embedded tissue 
sections with proven good reactivity. Negative controls were per-
formed by substituting the respective primary antibody by nonim-
mune serum. All cases were classifi ed or reclassifi ed according to 
the 2001 WHO Classifi cation. 
 Therapy 
 The initial therapy and therapeutic response [complete re-
sponse (CR), partial response (PR), progressive disease (PD), no 
response or relapse, subsequent therapies and follow-up] were 
 accurately documented for each case. A CR to treatment was de-
fi ned by the disappearance of all clinical evidence of disease and 
normalization of all laboratory values and radiographical results 
that had been abnormal before treatment. Treatment outcome was 
measured using overall survival. It was measured as the interval 
 Temmim /Baker /Amanguno /Madda /
Sinowatz 
 Oncology 2004;67:382–389 384
between the beginning of treatment and death or the date of the 
last follow-up evaluation. Patients were usually seen every 2 months 
in the fi rst year, every 3 or 4 months in the second and following 
years. 
 Results 
 From a total of 935 patients with extranodal lympho-
mas 821 (87.8%) were in the adult age group, 114 (12.2%) 
in the pediatric group ( table 1 ). Fifty-nine percent of the 
pediatric extranodal lymphomas were diagnosed in pa-
tients between 6 months and 6 years. The majority (58.8%) 
were 3–6 years old. The male to female ratio in the adult 
age group (2.1: 1) and in the pediatric group (2.0: 1) were 
similar. Kuwaiti patients accounted for 324 (39.5%) of 
the adult age group and 47 (41.2%) of the pediatric age 
group. The number of non-Kuwaiti patients included in 
our study was 504. Four hundred and twenty-eight were 
of Arabic origin (368 adults and 60 children), the 136 re-
maining patients (129 adults and 7 children) originated 
from non-Arab origin (different Asian countries). Median 
follow-up time was 47.0 months, with a range of 1–170 
months. 
 Patients who presented with extranodal NHL had lo-
calizations in a wide variety of organs ( table 2 ). The di-
gestive tract (stomach 19.8%; small intestine 9.8% and 
colon/rectum 5.8%) and the skin (17.8%) were the sites 
most frequently involved. In children, 57 cases (50%) of 
primary bowel lymphoma were observed ( table 3 ). The 
majority affected the large intestine (30.7%), mainly at 
the ileocecal junction. 17.8% involved the small intestine, 
mainly the ileum. Bulky disease was found in 47.5% of 
the adult age group. In 129 cases (15.7%), the tumor mass 
was equal or larger than 10 cm in diameter. A much high-
er percentage of bulky disease was found in children. 
61.4% of the patients in the pediatric group displayed 
bulky disease, 22 of them (19.3%) had tumors equal or 
larger than 10 cm in diameter. The majority of NHL in 
adults ( table 4 ) was DLBCL (58.6%), followed by MF 
(14.4%). In the pediatric group more than two thirds 
(77.2%) were Burkitt´s lymphoma (BL). DLBCL was also 
important with a percentage of 14.0%. 
 Most of the patients (73.6% of the adults and 88.6% of 
the children) received chemotherapy treatment ( table 5 ). 
Radiotherapy was used in adults in 7.3% of cases. A com-
bination of chemotherapy and radiotherapy was per-
formed in 22.8% of the adults and 10.5% of the children. 
Many patients responded favorably to the therapy: 71.4% 
of the adults and 63.2% of the children showed a CR, and 
12.8% of adults and 14.1% in the pediatric group showed 
at least a partial response. No response was seen in 21.9% 
of the children and 13.6% of the adults. 27.5% of the pa-
tients in the adult group during the observed period, and 
a considerably higher percentage of the children (39.5%) 
did not survive. 
 A positive family history was found in 8 cases of adult 
patients ( table 5 ). Four were males and four were females. 
Median age was 48 years, ranging from 15 to 65 years. 
Stomach lymphoma represents 37.5% followed by thy-
mus 25.0%, one case of heart, tonsil and skin MF. Most 
of the cases were Kuwaitis. They represented 75%, and 
the remaining 25% were Jordanians. 75% of the family 
Table 1. Clinical and pathological features of extranodal lympho-
mas
Clinical presentation Adults Pediatric (0–15)
Number 821 (87.8%) 114 (12.2)
Sex
Male
Female
559 (68.1%)
262 (31.9%)
176 (66.7%)
138 (33,.3%)
Age groups (years)
10–5
15–9
10–19
20–29
30–39
40–49
50–59
60+
139 (4.8)
127 (15.5)
178 (21.7)
167 (20.3)
134 (17.4)
167 (20.3)
143 (37.7)
137 (32.5)
134 (29.8)
Extranodal sites Stomach: 19.7%
Skin: 17.8%
Small intestine: 
9.8%
Bowel: 50.0%
Pharynx: 12.3%
Ovary: 9.6%
Nodal involvement 493 (60%) 101 (57.9)
LDH
High
Normal
330 (40.2%)
491 (59.8%)
166 (57.9%)
148 (42.1%)
Performance status 772 (94.0%) 106 (93.0%)
Systemic status
Fever
Weight loss
321 (39.1%)
246 (30.0%)
223 (27.2%)
171 (62.3%)
163 (55.3%)
153 (46.5%)
Stage IE 33.1%
IIE 40.3%
III 37.6%
IV 27.7%
Bulky disease
>10 cm
392 (47.8%)
132 (33.7%)
172 (63.2%)
123 (32.0%)
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members affected were fi rst degree relatives (mother, son, 
siblings) and the remaining 25% were cousins. Lympho-
ma in the family members was mostly found in lymph 
nodes (75%); the remaining 25% was in the stomach and 
spleen. Half of the lymphomas among family members 
were NHL, Hodgkin’s lymphoma, respectively. 
 Eleven cases of extranodal lymphomas that evolved in 
patients who previously underwent organ transplantation 
could be documented. Eight cases (72.7%) originated in 
males. Median age was 57 years, age range extended from 
4 to 69 years. Regarding to the transplanted organ, most 
of the cases were kidney transplantations (72.7%). Two 
Site Kuwaiti Arab Non -Arab Total
n % n % n % n %
Stomach 68 21.0 79 21.2 16 12.8 163 19.8
Skin 72 22.2 56 15.1 18 14.4 146 17.8
Small intestine 20 16.2 35 19.4 25 20.0 180 19.8
Waldeyer’s ring 20 13.1 38 17.8 14 19.6 172 18.8
Bone/Soft tissue 24 17.4 24 16.5 13 10.4 161 17.4
Colon/Rectum 15 14.7 22 15.9 10 18.0 147 15.8
Brain/CNS 17 12.2 19 15.1 15 14.0 131 13.8
Salivary/Lacrimal gland 17 15.2 11 13.0 12 11.6 130 13.7
Thyroid 13 14.0 11 13.0 11 10.8 125 13.0
Thymus 17 12.2 18 12.2 17 15.6 122 12.7
Spleen 18 12.5 12 13.2 11 10.8 121 12.6
Oral Cavity 17 12.2 17 11.9 13 12.4 117 12.0
Liver 15 11.5 10 12.7 11 10.8 116 11.9
Kidney 16 11.9 19 12.4 10 10.0 115 11.8
Testis 18 12.5 16 11.6 10 10.0 114 11.7
Pancreas 17 12.2 13 10.8 13 12.4 113 11.6
Lung/Pleura 16 11.9 14 11.1 11 10.8 111 11.3
Cervix/Vagina 14 11.2 14 11.1 12 11.6 110 11.2
Accessory inuses 11 10.3 17 11.9 10 10.0 118 11.0
Ovary 11 10.3 12 10.5 12 11.6 115 10.6
Heart 13 10.9 11 10.3 10 10.0 114 10.5
Breast 13 10.9 11 10.3 10 10.0 114 10.5
Urinary bladder 12 10.6 10 10.0 10 10.0 112 10.2
Prostate 10 10.0 11 10.3 10 10.0 111 10.1
Larynx 10 10.0 11 10.3 10 10.0 111 10.1
Bone marrow 10 10.0 11 10.3 10 10.0 111 10.1
Site Kuwaiti Arab Non -Arab Total
n % n % n % n %
Intestine 21 44.7 30 50.0 6 85.7 157 150.0
Pharynx 16 12.8 19 0 10.0 115 112.3
Ovary 15 10.6 16 10.0 0 10.0 111 119.6
Bone 15 10.6 14 16.7 1 14.3 110 118.8
Thymus 16 12.8 13 15.0 0 10.0 119 117.9
Testis 11 12.1 17 11.7 0 10.0 118 117.0
Skin 12 14.2 10 10.0 0 10.0 112 111.8
Kidney 11 12.1 10 10.0 0 10.0 111 110.9
Parotid 10 10.0 11 11.7 0 10.0 111 110.9
Accessory sinuses 11 12.1 10 10.0 0 10.0 111 110.9
Total 47 60 7 114 100
Table 2. Localization, frequency and 
percentage of site (organ) involvement 
of primary extranodal lymphomas in 
adults
Table 3. Localization, frequency and 
percentage of site (organs) of primary 
extranodal lymphoma in pediatric 
age group
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of the other 3 remaining cases occurred after bone mar-
row transplantation and only one case was found after the 
transplantation of liver. 63.6% of the lymphomas seen 
after organ transplantation were DLBCL, 18.20% were 
intestinal. Anaplastic large cell lymphoma and BL were 
represented by only one case each. Seven cases (63.60%) 
of lymphomas post-transplantation were stage I–II, 4 cas-
es (36.40%) were stage III–IV. Median follow-up time for 
these patients was 5 months ranging from 1 to 60 months, 
with overall survival rate of 28.0  8 16.4 after 12 
months. 
 Discussion 
 NHL is one among the small number of malignant tu-
mors with a markedly increasing incidence and mortality 
rates in the recent past. This trend is particularly obvious 
in industrialized countries  [11], but is also seen in devel-
oping countries. Iatrogenic immunosupression as well as 
numerous diseases associated with an impaired immune 
system, like acquired immunodefi ciency syndrome, have 
been clearly recognized as etiological factors. Among the 
NHL, primary extranodal lymphomas are an important 
group of disease with diverse etiology, pathogenesis, pat-
tern of presentation and outcome  [12] . The gastrointesti-
nal tract is the most common presenting site, but extra-
nodal lymphomas have been virtually reported from 
every organ. Most are B-cell, DLCBL. Follicular histol-
ogy is considerably less common. 
 In an extensive study, Newton et al.  [4]   described the 
epidemiology and geographical distribution of NHL in 
different countries. The authors used site-specifi c infor-
mation of NHL from thirty-nine cancer centers in four-
teen countries, including Kuwait. The incidence rate for 
all NHL combined varied from a low 2 per 100,000 per 
year in Thailand to about 10 per 100,000 in Caucasians 
in the USA. Across Europe, there was roughly a 2-fold 
Pathology Adults Pediatrics
Diffuse large B-cell lymphoma 481 158.6% 116 114.0%
Mycosis fungoides 118 114.4% 112 111.8%
Marginal zone B Malt
Marginal zone B Malt
Composite marginal Zone/DLBC
186
178
118
110.5%
119.5%
111.0%
B follicular lymphoma
B follicular lymphoma grade 1
B follicular lymphoma grade 2
B follicular lymphoma grade 3
Composite BFL3/DLBC
138
113
113
110
112
114.6%
111.6%
110.4%
111.2%
111.5%
Peripheral T-cell lymphoma
Intestinal
Peripheral T-cell lymphoma, unspecifi ed
Lymphoepithelial lymphoma
131
117
112
    2
113.8%
112.1%
111.5%
110.2%
111 110.9%
Anaplastic large cell lymphoma
T-anaplastic large cell
B-anaplastic large cell
116
113
113
113.5%
111.6%
110.4%
111 110.9%
Burkitt’s lymphoma 131 113.9% 188 177.2%
Small lymphocytic lymphoma 119 111.1%
Pre-T-lymphoblastic lymphoma 113 110.4% 112 111.8%
Splenic marginal zone lymphoma 113 110.4%
Mantle cell lymphoma 112 110.2%
Intravascular lymphoma 111 110.1%
Pre-B-lymphoblastic lymphoma 111 110.1%
T-lymphoblastic lymphoma 111 110.1% 114 113.5%
Total 821 100% 114 100%
Table 4. Histopathology of extranodal 
non-Hodgkin lymphomas
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difference observed from about 4 per 100,000 in Slovakia 
to about 8 per 100,000 in The Netherlands. The total pro-
portion classifi ed as being of extranodal origin ranged 
from to 22–25% of all lymphomas in the USA to 33% in 
Denmark and 34% in Israel. France (42%) and Kuwait 
(43%) had particularly high relative extranodal lympho-
ma frequencies. 
 The relative incidence of the subtypes of NHL is also 
known to differ according to the geographical location 
 [13–15] . From a cohort of 1,403 cases of NHL at nine 
study sites around the world that consisted of consecutive 
patients seen between 1988 and 1990, 31% presented as 
DLBCL, and 22% as follicular lymphomas. In a second 
major study, as part of a clinical evaluation of the Inter-
national Lymphoma Study Group (ILSG), 1,378 NHL 
were classifi ed from eight different geographic sites (Oma-
ha, USA; Vancouver, Canada; Cape town, South Africa; 
London, UK; Würzburg/Göttingen, Germany; Lyon, 
France; Locarno/Bellinzona, Switzerland; and Hong 
Kong, China)  [14] . Substantial differences were found in 
the distribution of the major subtypes of NHL: A greater 
percentage of follicular lymphoma was seen in North 
America, UK and South Africa (31%) versus only 14% in 
other sites. Peripheral T-cell lymphoma was most com-
mon in London, Cape Town and Hong Kong (9%), where-
as all other sites had a much lower incidence (average 3%). 
In Switzerland higher percentages of mediastinal large B-
cell lymphoma (9 vs. 2% elsewhere) and mantle cell lym-
phoma (14 vs. 6% elsewhere) were observed. In Kuwait, 
DLBCL with 58.6% of all NHL was by far the most com-
mon malignancy of the immune system in the adult group. 
Follicular lymphomas were considerably less frequent, 
accounting for only 4.6% of the cases. In a recent study 
of ILSG  [12], a much higher number of follicular lym-
phoma (22%) was found in nine sites around the world. 
In children, the far most common malignancy in our 
study was BL (77.2%), followed by DLBCL (14%). Our 
results confi rm and extend older studies on NHL in the 
Middle East  [16, 17] , demonstrating a high incidence of 
extranodal lymphomas in this area. In a recent study in 
Bahrain  [18] , also a remarkable high number of primary 
extranodal lymphomas (41.7% of NHL) was found. This 
study and our results highlight common features of ma-
lignant lymphomas from countries of the Arabian Gulf 
region. The observed regional pattern distinguish them 
from lymphomas in the Western world, but the reasons 
for the high incidence of extranodal lymphomas in the 
Arabian Gulf region are largely unknown. It has been put 
forward  [4] that this may be due to special ethnic or local 
environmental conditions, but our data do not support 
this assumption. Recent results from the KCCC  [19] 
show that our Asian patients show a similar high number 
of extranodal lymphomas as Arabian people, excluding 
the hypothesis of an ethnic disposition. As the KCCC also 
treats a high number of lymphoma cases from the neigh-
boring Gulf States (Saudi Arabia, Bahrain, Oman) and 
from other countries of the Middle East (Egypt, Syria, 
Lebanon, Yemen, Jordan), who also show a high inci-
dence of extranodal NHL, a local environmental factor 
can be ruled out for Kuwait. 
 Our fi nding also supports the opinion that the distribu-
tion of NHL subtypes differs by geographic region  [4] . In 
our study, the most common site of extranodal lympho-
ma involvement was the stomach (19.9%) followed by the 
skin (17.8%). The percentage of all lymphomas found in 
the stomach varies signifi cantly in different countries. It 
ranged from 3% in Costa Rica to 10% in Italy and Spain 
 [4] . In Kuwait the incidence of gastric and small intestine 
disease is especially high. In industrialized countries, 
small bowel cancers are predominantly adenocarcino-
Table 5. Therapies and course of extranodal lymphomas
Adults Pediatric
Number 821 (87.8%) 114 (12.2%)
Initial therapy
CTH
RTH
Combination
Salvage
604 (73.6%)
160 (7.3%)
198 (22.8%)
187 (22.8%)
101 (88.6%)
112 (10.5%)
125 (21.9%)
Course
CR
PR
No response
Death
Alive
LFU
586 (71.4%)
105 (12.8%)
112 (13.6%)
226 (27.5%)
543 (66.1%)
249 (30.3%)
172 (63.2%)
116 (14.1%)
125 (21.9%)
145 (39.5%)
163 (55.3%)
123 (20.2%)
Stem cell support PSCT: 8 (1.0%)
BMT: 4 (0.5%)
BMT: 1 
(0.9%)
Family history 118 (1.0%)
Second malignancy 117 (0.9%) 111 (0.9%)
Post organ transplant
Kidney
Liver
BMT
117 (0.9%)
119 (1.1%)
111 (1.0%)
111 (1.0%) 111 (0.9%)
CTH = Chemotherapy; RTH = radiotherapy; CR = complete 
remission; PR = partial remission; BMT = bone marrow transplan-
tation; LFU = last follow-up.
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mas, whereas in developing countries, lymphomas are 
much more common  [20] . Therefore, geographical and 
ethnical differences in the incidence of extranodal lym-
phomas at special sites show some interesting pattern that 
may not only refl ect differences in coding practice, but 
also rather true variations in the incidence of extranodal 
lymphomas in various organs. 
 The male to female ratio for NHL in North American 
was 1.5:  1 for the Caucasian population and 1.7:  1 for Af-
rican Americans  [21] . Only lymphoma of the thyroid was 
more common in women (0.4:  1) excluding sex-specifi c 
sites. For gastrointestinal NHL  [22] , found in a 15-year 
series in France, an age-standardized incidence rate of 
0.94 per 100,000 for men, and a signifi cantly smaller in-
crease of 0.54 per 100,000 for women was seen. In our 
study the male to female ratio, both in the adult age group 
(2.1:  1) and in the pediatric group (2.0:  1), was shifted to-
wards a signifi cantly higher percentage of male patients. 
 A worldwide study of the International Agency for Re-
search of Cancer, involving more than fi fty countries, has 
provided data that the highest incidence of BL occurred 
in tropical Africa and Papua New Guinea  [23] . Else-
where, BL was rare, though the incidence was somewhat 
higher in Spain and North Africa. In Kuwait, NHL in 
children is the second most common malignant tumor 
 [24] . We could demonstrate that the overwhelming ma-
jority (77.2%) was BL followed by DLBCL. Nearly 90% 
(88.6%) of the patients in the pediatric group had nodal 
involvement, and in half of them the bowel was affected. 
In children also, the majority of extranodal lymphomas 
was found to be in stage III and IV. The course showed a 
somewhat less favorable response to treatment in chil-
dren (CR of 63.2% in children compared to 71.4% in 
adults) and the nonresponse rate was 21.9% compared to 
13.6% in the adult group. Death rate in the pediatric 
group (39.5%) was considerably higher than in adults 
(27.5%), but a recent study done in Kuwait demonstrated 
that the treatment of NHL according to the BFM 95 pro-
tocol could signifi cantly improve the overall survival and 
disease-free interval  [25] . 
 Cancer incidence in patients who undergo transplan-
tation varies considerably and ranges from 4 to 18%  [23] . 
In an extensive study with 6,798 post-transplantation pa-
tients, Penn  [25] demonstrated that lymphomas are 
among the predominant malignancies after organ trans-
plantation. In our patients 11 cases of extranodal lympho-
mas were found after organ transplantation, mainly of the 
kidney. All of them developed aggressive disease with 
poor prognosis. No cases of NHL associated with AIDS 
were found in our study. 
 In summary, our retrospective study demonstrated 
that extranodal lymphomas accounted for nearly half 
(45%) of all NHL diagnosed in the KCCC in the period 
between January 1985 and December 2000. The reasons 
for this high incidence, also observed in other countries 
of the Arabian Gulf region, are largely unknown. In the 
future, new techniques such as cytogenetic molecular 
analyses to identify subtype-specifi c etiological factors, 
evaluations of polymorphisms in genes involved in im-
mune function, and the study of the role of environmen-
tal and occupational chemicals in NHL in Kuwait will 
help to clarify these questions. 
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